Stifel Financial
XENE icon

Stifel Financial’s Xenon Pharmaceuticals XENE Stock Holding History

Stifel Financial’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$992K Sell
16,442
-276
-2% -$15.3K ﹤0.01% 2567
2026
Q1 		$972K Sell
16,718
-830
-5% -$38.2K ﹤0.01% 2472
2025
Q4 		$787K Sell
17,548
-1,167
-6% -$49K ﹤0.01% 2583
2025
Q3 		$751K Sell
18,715
-1,907
-9% -$67.2K ﹤0.01% 2566
2025
Q2 		$645K Buy
20,622
+95
+0.5% +$3.1K ﹤0.01% 2611
2025
Q1 		$689K Sell
20,527
-161
-0.8% -$6.11K ﹤0.01% 2468
2024
Q4 		$811K Sell
20,688
-883
-4% -$36.5K ﹤0.01% 2386
2024
Q3 		$849K Sell
21,571
-512
-2% -$20.6K ﹤0.01% 2340
2024
Q2 		$861K Sell
22,083
-92
-0.4% -$3.68K ﹤0.01% 2262
2024
Q1 		$955K Buy
22,175
+1,294
+6% +$59.5K ﹤0.01% 2213
2023
Q4 		$962K Buy
20,881
+401
+2% +$14.2K ﹤0.01% 2169
2023
Q3 		$700K Buy
20,480
+399
+2% +$14.9K ﹤0.01% 2294
2023
Q2 		$773K Buy
20,081
+9,777
+95% +$389K ﹤0.01% 2244
2023
Q1 		$369K Buy
10,304
+360
+4% +$13.3K ﹤0.01% 2686
2022
Q4 		$392K Sell
9,944
-100
-1% -$3.64K ﹤0.01% 2611
2022
Q3 		$363K Hold
10,044
– – ﹤0.01% 2626
2022
Q2 		$306K Sell
10,044
-823
-8% -$24.9K ﹤0.01% 2738
2022
Q1 		$332K Sell
10,867
-617
-5% -$18.5K ﹤0.01% 2815
2021
Q4 		$358K Buy
11,484
+556
+5% +$16.6K ﹤0.01% 2804
2021
Q3 		$167K Buy
+10,928
New +$190K ﹤0.01% 3163
2018
Q3 		– Sell
-11,500
Closed -$106K – 2828
2018
Q2 		$106K Sell
11,500
-375
-3% -$2.33K ﹤0.01% 2629
2018
Q1 		$58K Sell
11,875
-10,325
-47% -$38.2K ﹤0.01% 2614
2017
Q4 		$63K Buy
22,200
+500
+2% +$1.36K ﹤0.01% 2580
2017
Q3 		$65K Buy
+21,700
New +$67.1K ﹤0.01% 2504

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Stifel Financial's XENE Position: Q2 2026 in Review

Stifel Financial reduced its Xenon Pharmaceuticals (XENE) stake by 1.7% in Q2 2026, selling an estimated $15.3K and leaving 16,442 shares worth $992K. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Stifel Financial first reported a position in XENE in Q3 2017 and has held it in 24 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Stifel Financial held 16,442 shares of Xenon Pharmaceuticals worth $992K as of Q2 2026.
  • Stifel Financial sold 276 Xenon Pharmaceuticals shares in Q2 2026, an estimated $15.3K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2567 holding.
  • Stifel Financial first reported a position in Xenon Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.